Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent

Biochemical Pharmacology

Volumn 58, Issue 6, 1999, Pages 1057-1066

  Walker, Denise L ^a   Reid, Joel M ^a,b   Svingen, Phyllis A ^a   Rios, Robert ^a   Covey, Joseph M ^c   Alley, Michael C ^c   Hollingshead, Melinda G ^c   Budihardjo, I Imawati ^a   Eckdahl, Steven ^a   Boerner, Scott A ^a   Kaufmann, Scott H ^a,b   Ames, Matthew M ^a,c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c Developmental Therapeutics Program   (United States)

Author keywords

6 Aminonicotinamide; Cisplatin; Pharmacokinetics

Indexed keywords

6 AMINONICOTINAMIDE; CISPLATIN; DRUG METABOLITE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CANCER CELL CULTURE; CELL STRAIN K 562; COLONY FORMING UNIT; CONTROLLED STUDY; DNA ADDUCT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SENSITIZATION; DRUG TISSUE LEVEL; DRUG URINE LEVEL; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LETHALITY; LIVER; LUNG CANCER; MALE; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; SPLEEN;

6-AMINONICOTINAMIDE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CISPLATIN; DRUG INTERACTIONS; HUMANS; K562 CELLS; MICE; NAD; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0032779015     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00179-3     Document Type: Article

References (33)

1. Johnson W.J., McColl J.D. 6-Aminonicotinamide - A potent nicotinamide antagonist. Science. 122:1955;834.
2. Berger N.A., Catino D.M., Vietti T.J. Synergistic antileukemic effect of 6-aminonicotinamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on L1210 cells in vitro and in vivo. Cancer Res. 42:1982;4382-4386.
3. Berger N.A., Berger S.J., Hirschler N.V. Pyridine Nucleotide Metabolism as a Target for Cancer Chemotherapy. 1989;pp. 366-371. Springer, New York.
4. Budihardjo I.I., Walker D.L., Svingen P.A., Buckwalter C.A., Desnoyers S., Eckdahl S., Shah G.M., Poirier G.G., Reid J.M., Ames M.M., Kaufmann S.H. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res. 4:1998;117-130.
5. 31P NMR investigation of effect of 6-aminonicotinamide on metabolism of RIF-1 tumor cells in vitro. J Biol Chem. 271:1996;4113-4119.
6. Stolfi R.L., Colofiore J.R., Nord L.D., Koucher J.A., Martin D.S. Biochemical modulation of tumor cell energy Regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination . Cancer Res. 52:1992;4074-4081.
7. Koutcher J.A., Alfieri A.A., Stolfi R.L., Devitt M.L., Colofiore J.R., Nord L.D., Martin D.S. Potentiation of a three drug chemotherapy regimen by radiation. Cancer Res. 53:1993;3518-3523.
8. Martin D.S., Stolfi R.L., Colofiore J.R., Nord L.D., Sternberg S. Biochemical modulation of tumor cell energy in vivo II. A lower dose of adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed . Cancer Invest. 12:1994;296-307.
9. Martin D.S., Stolfi R.L., Colofiore J.R., Nord L.D. Marked enhancement in vivo of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation. Anticancer Res. 7:1996;655-659.
10. Chatterjee S., Hirota H., Belfi C.A., Berger S.J., Berger N.A. Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78. Cancer Res. 57:1997;5112-5116.
11. Pike B.L., Robinson W.A. Human bone marrow colony growth in agar-gel. J Cell Physiol. 76:1970;77-84.
12. Adjei A.A., Budihardjo I.I., Rowinsky E.K., Kottke T.J., Svingen P.A., Buckwalter C.A., Grochow L.B., Donehower R.C., Kaufmann S.H. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro. Inhibition of platinum-DNA adduct removal. Clin Cancer Res. 3:1997;761-770.
13. Tothill P., Matheson L.M., Smyth J.F., McKay K. Inductively coupled plasma mass spectrometry for the determination of platinum in animal tissues and a comparison with atomic absorption spectrometry. J Anal Atom Spectrom. 5:1990;619-622.
14. Casetta B., Roncadin M., Montanari G., Furlanut M. Determination of platinum in biological fluids by ICP-mass spectrometry. Atom Spectrom. 12:1991;81-86.
15. Robbins M.E.C., Bywaters T., Jaenke R.S., Hopewell J.W., Matheson L.M., Tothill P., Whitehouse E. Long-term studies of cisplatin-induced reductions of porcine renal function reserve. Cancer Chemother Pharmacol. 29:1992;309-315.
16. Allain P., Berre S., Mauras Y., LeBouil A. Evaluation of inductively coupled mass spectrometry for the determination of platinum in plasma. Biol Mass Spectrom. 21:1992;141-143.
17. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N., Poirier G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase An early marker of chemotherapy-induced apoptosis . Cancer Res. 53:1993;3976-3985.
18. Stratford M.R.L., Dennis M.F. Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. Cancer Chemother Pharmacol. 34:1994;399-404.
19. Stratford M.R.L., Dennis M.F. High-performance liquid chromatographic determination of nicotinamide and its metabolites in human and murine plasma and urine. J Chromatogr B Biomed Appl. 582:1992;145-151.
20. Dietrich L.S., Friedland I.M., Kaplan L.A. Pyridine nucleotide metabolism Mechanism of action of the niacin antagonist, 6-aminonicotinamide . J Biol Chem. 233:1958;964-968.
21. Herken H., Lange K., Kolbe H. Brain disorders induced by pharmacological blockade of the pentose phosphate pathway. Biochem Biophys Res Commun. 36:1969;93-100.
22. Halliday S.L., Sloboda A., Will L.W. 6-Aminonicotinamide and related niacin antagonists. Fedn Proc. 16:1957;190-191.
23. McColl J.D., Rice W.B., Adamkiewicz V.W. Inhibition of Walker carcinoma by 6-aminonicotinamide. Can J Biochem Physiol. 35:1957;795-798.
24. Shapiro D.M., Dietrich L.S., Shils M.E. Quantitative biochemical differences between tumor and host as a basis for cancer chemotherapy. V. Niacin and 6-aminonicotinamide. Cancer Res. 17:1956;600-604.
25. Herter F.P., Weissman S.G., Thompson H.G. Jr, Hyman G., Martin D.S. Clinical experience with 6-aminonicotinamide. Cancer Res. 21:1961;31-37.
26. Perlia C.P., Kofman S., Sky-Peck H., Taylor S.I. Clinical use of 6-aminonicotinamide in patients with disseminated neoplastic disease. Cancer. 14:1961;644-648.
27. Cowan D.H., Alison R.E. Evaluation of 6-aminonicotinamide (NSC-21206) in the treatment of metastatic hypernephroma. Cancer Chemother Rep. 54:1970;175-179.
28. Belfi C.A., Chatterjee S., Gosky D.M., Berger S.J., Berger N.A. Colon cancer cells exhibit increased in vitro sensitivity to cross-linking alkylating agents after 6-aminonicotinamide treatment. Proc Am Assoc Cancer Res. 37:1996;377.
29. Sternberg S.S., Philips F.S. 6-Aminonicotinamide and acute degenerative changes in the central nervous system. Science. 127:1958;644-645.
30. Keller K., Kolbe H., Herken H., Lange K. Glycolysis and glycogen metabolism after inhibition of hexose monophosphate pathway in C6-GLIAL cells. Naunyn Schmiedebergs Arch Pharmacol. 294:1976;213-215.
31. Varnes M.E. Inhibition of pentose cycle of A549 cells by 6-aminonicotinamide Consequences for aerobic and hypoxic radiation response and for radiosensitizer action . NCI Monogr. 6:1988;199-203.
32. Zhang J., Dawson V.L., Dawson T.M., Snyder S.H. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science. 265:1994;722-723.
33. Eliasson M.J., Sampei K., Mandir A.S., Hurn P.D., Traystma R.J., Bao J., Pieper A., Wang Z.Q., Dawson T.M., Snyder S.H. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral-ischemia. Nat Med. 3:1997;1089-1095.